Cardiol Therapeutics (CRDL) Accounts Payables (2020 - 2025)

Cardiol Therapeutics has reported Accounts Payables for 6 years, with the latest figure at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 50.05% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $2.5 million (down 50.05% YoY), and the FY2025 full-year result was $2.5 million, down 50.05% from the prior year.
• Accounts Payables for Q4 2025 stood at $2.5 million, down from $5.0 million in the prior quarter.
• The five-year high for Accounts Payables was $6.9 million in Q4 2022, with the low at $2.5 million in Q4 2025.
• Historically, Accounts Payables has averaged $4.8 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2021 — Accounts Payables surged 103.78% — and 2025, when it tumbled 50.05%.
• Cardiol Therapeutics' Accounts Payables stood at $3.9 million in 2021, then soared by 78.37% to $6.9 million in 2022, then dropped by 14.1% to $5.9 million in 2023, then decreased by 15.45% to $5.0 million in 2024, then plunged by 50.05% to $2.5 million in 2025.
• The last three Accounts Payables figures came in at $2.5 million (Q4 2025), $5.0 million (Q4 2024), and $5.9 million (Q4 2023), per Business Quant data.